Background Despite advances in therapeutics for adverse‐risk acute myeloid leukaemia
(AML), overall survival remains poor, especially in refractory disease. Comprehensive …

Introduction: Acute undifferentiated leukemia (AUL) is a rare subtype of acute leukemia. It is
characterized by lack of expression of myeloid or lymphoid lineage markers, frequently …

Leukemic or blast phase transformation occurs in~ 2.3–14.4% of patients with polycythemia
vera at 10 years and 5.5–18.7% at 15 years; the corresponding rates for essential …

Characterization of genetic aberrations in acute myeloid leukemia (AML) has substantially
improved our understanding of the pathogenesis of this disease and is of growing …

Introduction: The outcomes of patients (pts) with post-MPN AML are poor, and there is no
standard treatment. The Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib (RUX) markedly …

Purpose: The prognosis of patients with relapsed/refractory (R/R) acute myeloid leukemia
(AML) remains poor, and novel therapies are needed. The proteasome pathway represents …

6526 Background: Progression to blast phase (BP) occurs in about 10% of patients with
BCR-ABL-negative myeloproliferative neoplasms (MPN) and is associated with an …

Background: Inhibitory killer-cell immunoglobulin receptors (KIRs) negatively regulate NK
cell-mediated killing of HLA class I-expressing tumors. Lack of KIR-HLA class I interactions …

Introduction Despite impressive response rates of> 70% in frontline therapy with Azacitidine
and Venetoclax, relapsed/refractory (R/R) acute myeloid leukemia (AML) remains a clinical …

1. Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am
Soc Hematol Educ Program. 2011; 2011: 43-50. 2. Walsby EJ, Coles SJ, Knapper S, Burnett …